Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: An analytical review

Lingyi Zhang, Guqi Wang, Weihong Hou, Ping Li, Andrea Dulin, Herbert L. Bonkovsky – 25 January 2010 – Chronic hepatitis B (CHB) is major global health problem. In China, where about 120,000,000 persons are chronically infected, CHB has been treated for centuries with traditional Chinese medicines (TCMs). This review summarizes and meta‐analyzes the results of randomized controlled trials (RCTs) of TCM formulations reported in China in 1998‐2008 for treatment of CHB.

Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

Vlad Ratziu, Fréderic Charlotte, Carole Bernhardt, Philippe Giral, Marine Halbron, Gilles LeNaour, Agnès Hartmann‐Heurtier, Eric Bruckert, Thierry Poynard, LIDO Study Group – 25 January 2010 – Short‐term trials of glitazones in nonalcoholic steatohepatitis (NASH) yielded controversial histological results. Longer treatment might result in additional improvement. After a 1‐year randomized trial, 53 patients underwent a control liver biopsy and were enrolled in an open‐label extension trial of rosiglitazone (RSG), 8 mg/day for 2 additional years.

CX3CL1 (fractalkine): A signpost for biliary inflammation in primary biliary cirrhosis

Shinji Shimoda, Kenichi Harada, Hiroaki Niiro, Akinobu Taketomi, Yoshihiko Maehara, Koichi Tsuneyama, Kentaro Kikuchi, Yasuni Nakanuma, Ian R. Mackay, M. Eric Gershwin, Koichi Akashi – 25 January 2010 – Improvements in the treatment of primary biliary cirrhosis (PBC) may depend upon dissection of mechanisms that determine recruitment of mononuclear cells to intralobular bile ducts, including the role of the chemokine‐adhesion molecule CX3CL1 (fractalkine).

Selection‐driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection

Michael J. Fuller, Naglaa H. Shoukry, Toshifumi Gushima, David G. Bowen, Benoit Callendret, Katherine J. Campbell, Dana L. Hasselschwert, Austin L. Hughes, Christopher M. Walker – 25 January 2010 – Immune escape driven by selection pressure from virus‐specific CD8 T cells has been demonstrated in both chimpanzees and humans infected with the hepatitis C virus (HCV).

Reply:

Robin Haring, Henri Wallaschofski, Matthias Nauck, Marcus Dörr, Sebastian E. Baumeister, Henry Völzke – 25 January 2010

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg‐positive chronic hepatitis B

Hyun Woong Lee, Heon Ju Lee, Jae Seok Hwang, Joo Hyun Sohn, Jae Young Jang, Ki Jun Han, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong Han Paik, Chun Kyon Lee, Kwan Sik Lee, Chae Yoon Chon, Kwang‐Hyub Han – 25 January 2010 – The reported durability of virologic response after successful lamivudine monotherapy is variable, and the question remains as to whether virologic responses can be maintained over an extended follow‐up period.

Subscribe to